# Study to Investigate the Efficacy of Elbasvir/Grazoprevir Fixed-Dose Combination for 8 Weeks in Treatment-Naïve, HCV GT1b-Infected Patients, With Non-severe Fibrosis

> **NCT02973503** · PHASE3 · COMPLETED · sponsor: **University Hospital, Clermont-Ferrand** · enrollment: 117 (actual)

## Conditions studied

- Chronic HCV Infection

## Interventions

- **DRUG:** Elbasvir/Grazoprevir Fixed Dose Combination

## Key facts

- **NCT ID:** NCT02973503
- **Lead sponsor:** University Hospital, Clermont-Ferrand
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-01-11
- **Primary completion:** 2018-11-10
- **Final completion:** 2019-04
- **Target enrollment:** 117 (ACTUAL)
- **Last updated:** 2020-10-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02973503

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02973503, "Study to Investigate the Efficacy of Elbasvir/Grazoprevir Fixed-Dose Combination for 8 Weeks in Treatment-Naïve, HCV GT1b-Infected Patients, With Non-severe Fibrosis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02973503. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*